O’Brien, Gary L. http://orcid.org/0000-0001-7112-4324
O’Mahony, Denis
Gillespie, Paddy
Mulcahy, Mark
Walshe, Valerie
O’Connor, Marie N.
O’Sullivan, David
Gallagher, James
Byrne, Stephen
Funding for this research was provided by:
Irish Research Council (GOIPG/2016/635)
Health Research Board (HRA_HSR/2010/14)
Article History
First Online: 13 July 2018
Compliance with Ethical Standards
:
: This research project was funded by the Health Research Board of Ireland (Grant HRA_HSR/2010/14) and the Irish Research Council (GOIPG/2016/635). The funders had no part in the design of the analysis, the collection, analysis and interpretation of the data, the writing of the report or the decision to submit the article for publication.
: Stephen Byrne and Denis O’Mahony have part ownership in a patent “A Prescription Decision Support System” (based on STOPP/START prescribing rules); the patent was registered with the European Patent Office (Munich); Patent no. 11757950.8–1952. Stephen Byrne and Denis O’Mahony are also involved with two European Commission-funded grants that involve clinical trials in which there is computerised deployment of the STOPP/START criteria as part of an intervention designed to optimise pharmacotherapy in older adults. The first European Commission grant is called “Development and clinical trials of a new Software Engine for the Assessment and Optimization of drug and non-drug Therapy in Older peRsons [SENATOR]”, grant agreement 305930, awarded under the Seventh Framework Programme (FP7). The trial is registered with the US National Institutes of Health (NCT02097654). Denis O’Mahony is coordinator of the SENATOR project. The second European Commission-funded project is called “OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly”. OPERAM is funded under the Horizon 2020 programme (PHC 17-2014). The OPERAM trial is based on another software intervention called “Screening Tool to Reduce Inappropriate Prescribing”, which uses STOPP/START rules to assess the pharmacotherapy of older people. The trial is registered with the US National Institutes of Health (NCT02986425). Gary L. O’Brien, Paddy Gillespie, Mark Mulcahy, Valerie Walshe, Marie N. O’Connor, David O’Sullivan and James Gallagher have no conflicts of interest that are directly relevant to the content of this article.
: The research ethics committee (institutional review board) of the local teaching hospitals network approved the trial protocol and the trial was registered with the US National Institutes of Health (NCT01467050).
: Written consent was sought and obtained from all participating patients prior to enrolment in the study.
: This article is classified as I19 according to the JEL system.